An FDA advisory committee voted 12 to 0 against placing ipamorelin on the list of bulk substances permitted for compounding, citing a lack of data supporting safety and efficacy. FDA separately lists ipamorelin acetate among substances that may present significant safety risks.
Compounding pharmacies sell sermorelin and ipamorelin together in a single vial, and the pairing has a real mechanistic rationale: the two act on different receptors, so combining a GHRH analog with a growth hormone secretagogue should produce more GH release than either alone. The rationale is sound. The evidence supporting this specific blend, and ipamorelin's regulatory standing, are considerably weaker than the marketing implies.
- The mechanism is genuine: different receptors, and GHRH plus a secretagogue is supra-additive in humans [2]
- That supra-additive effect was demonstrated with GHRP-6, not ipamorelin. Applying it to this blend is extrapolation [2]
- No published or registered trial has tested sermorelin plus ipamorelin in humans
- Ipamorelin's selectivity data comes from swine and rats, not humans [1]
- An FDA advisory committee voted 12 to 0 against permitting it for compounding [4]
- Its only published efficacy trial missed its endpoint [3]
Why the Combination Is Proposed
Sermorelin is a GHRH analog acting on GHRH receptors. Ipamorelin is a growth hormone secretagogue acting on the ghrelin receptor. Because these are separate pathways converging on the same pituitary cells, stimulating both should produce more GH than stimulating either alone.
That is not just theory. In normal subjects given GHRH and GHRP-6 separately and together, GH area under the curve was 686 for GHRH alone, 1787 for GHRP-6 alone, and 4111 for the combination, significantly higher than the arithmetic sum of the two [2]. That is genuine supra-additivity in humans.
It used GHRP-6, not ipamorelin, and GHRH, not sermorelin specifically. The principle that a GHRH analog plus a secretagogue is supra-additive is established. That this particular blend reproduces that magnitude is an extrapolation, and the "3 to 5 fold increase" figure circulating in marketing traces to website copy rather than to a trial.
What Is Actually Known About Ipamorelin
Ipamorelin was introduced as the first selective growth hormone secretagogue [1], and the selectivity claim is the main reason it is preferred over older GHRPs. In that work, ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation even at doses more than 200 times its GH ED50, while GHRP-6 and GHRP-2 did raise both.
Two qualifications matter. That study was conducted in swine and rats, not humans, so the cortisol selectivity claim rests on animal data. And the frequently repeated claim about prolactin is weaker than presented: the paper reports that none of the secretagogues tested affected prolactin, which makes it a property of the class in that experiment rather than an ipamorelin-specific advantage.
Ipamorelin's clinical development targeted postoperative ileus rather than body composition. The only published efficacy trial found a median time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo, which did not reach statistical significance [3]. Development was subsequently discontinued.
Ipamorelin's Regulatory Standing
This is where the blend differs most sharply from sermorelin alone, and it is rarely disclosed at point of sale.
FDA states there are no approved drug products containing ipamorelin in any form, and lists ipamorelin acetate among bulk drug substances for use in compounding that may present significant safety risks [5]. The agency's stated concerns are immunogenicity risk from aggregation or peptide-related impurities, the presence of unnatural amino acids complicating characterization, and published serious adverse events including death when ipamorelin was administered intravenously for gastric motility.
In October 2024, FDA's Pharmacy Compounding Advisory Committee voted on whether to place ipamorelin on the 503A bulks list. The vote was 0 in favor, 12 against, 1 abstention for both the free base and acetate forms [4], with the committee citing a lack of information supporting safety and efficacy in the available data.
| Sermorelin | Ipamorelin | |
|---|---|---|
| FDA-approved product | None currently | None, in any form [5] |
| On FDA safety-risk bulks list | Not listed | Listed [5] |
| Advisory committee vote | Not voted on | 0 for, 12 against [4] |
| Published efficacy trial outcome | Small positive adult studies | Primary endpoint not met [3] |
| Human selectivity data | Not applicable | Selectivity shown in swine [1] |
| WADA status | Prohibited, S2.2.4 [6] | Prohibited, S2.2.4 [6] |
No One Has Tested This Combination
A search of the published literature and the clinical trials registry returns no study, published or registered, testing sermorelin plus ipamorelin in humans. The papers that mention both are narrative reviews, one of which notes a paucity of data examining the clinical effects of these compounds.
So a blended vial is a product built on a plausible mechanism plus one human study of different molecules. That is not nothing, and it is also not what "clinically proven" means.
The Problem With a Fixed Ratio
A practical objection applies to blended vials independent of the evidence question, and it is clinical reasoning rather than a published finding. When two active peptides share one vial at a fixed ratio, you cannot adjust one without adjusting the other.
If a 90-day IGF-1 comes back above the age-adjusted range, the response is to reduce the GHRH analog. With a blend, that also reduces the secretagogue. If injection site reactions or appetite effects point to one component, you cannot isolate it. Separate vials cost more and require more injections, but they preserve the ability to titrate on evidence.
What to Ask Before Using a Blend
- What are the individual doses of each peptide in the vial, not just the combined strength?
- What evidence supports this specific ratio, as distinct from the general GHRH plus secretagogue rationale?
- Is the prescriber aware ipamorelin appears on FDA's safety-risk bulk substances list, and how do they weigh that?
- If my 90-day IGF-1 comes back high, how do we reduce one component without the other?
- Would separate vials be clinically preferable in my case?
Monotherapy remains the correct starting point. Establish that sermorelin alone moves your IGF-1 into range over 90 days before adding a second peptide. Starting on a blend means that if it works you will not know which component did the work, and if IGF-1 overshoots you will not know which to reduce.
Sermorelin with ipamorelin is two active peptides that only make sense against a starting IGF-1 and a 90-day retest. SystemLabs tests IGF-1 before prescribing and formulates the blend on clinical indication, so the protocol is built from your labs rather than a fixed template.
Frequently Asked Questions
Is a sermorelin ipamorelin blend better than sermorelin alone?
No published or registered trial has tested that combination in humans, so there is no direct evidence either way. The mechanistic rationale is sound: GHRH analogs and growth hormone secretagogues act on different receptors, and in humans GHRH combined with GHRP-6 produced a GH response significantly greater than the arithmetic sum of each alone [2]. Applying that result to sermorelin plus ipamorelin specifically is extrapolation.
Does ipamorelin raise cortisol?
The selectivity data says it does not, but that data is from swine and rats rather than humans. In the foundational study, ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation even at more than 200 times its GH ED50, while GHRP-6 and GHRP-2 did raise both [1]. No human cortisol study is available, so treat the claim as strongly suggested by animal data rather than demonstrated in people.
Is ipamorelin FDA approved?
No. FDA states there are no approved drug products containing ipamorelin in any form, and lists ipamorelin acetate among bulk substances for compounding that may present significant safety risks, citing immunogenicity potential, unnatural amino acids complicating characterization, and published serious adverse events including death with intravenous administration for gastric motility [5]. An FDA advisory committee voted 0 to 12 against permitting it for compounding [4].
Why did ipamorelin development stop?
It was developed for postoperative ileus rather than body composition, and the only published efficacy trial found a median time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo, which did not reach statistical significance [3]. Development was discontinued afterward. Note that its clinical testing was never aimed at the anti-aging or body composition uses it is now sold for.
Can I adjust the dose of a blended vial?
Not independently, and this is the practical drawback. A fixed-ratio vial means reducing one peptide necessarily reduces the other. If your 90-day IGF-1 comes back above the age-adjusted range, the appropriate response is to lower the GHRH analog, which a blend does not allow you to do in isolation. Separate vials cost more and require more injections but preserve the ability to titrate on lab results.
Is ipamorelin banned in sport?
Yes. The 2026 WADA Prohibited List names ipamorelin explicitly under section S2.2.4, in the growth hormone secretagogues bullet, alongside anamorelin, ibutamoren, and macimorelin [6]. Sermorelin appears in the same section under GHRH analogues. Both are prohibited at all times, in and out of competition, as non-specified substances.
References
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
